All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Is ibrutinib combined with venetoclax safe and effective in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
Firstly, Wang discusses key findings from the SYMPATICO study (NCT03112174) investigating ibrutinib + venetoclax vs ibrutinib + placebo in patients with R/R MCL; results showed longer median progression-free survival with ibrutinib + venetoclax vs ibrutinib + placebo (32 months vs 22 months, respectively) and higher overall response rates (82% vs 74%, respectively). The safety profiles between both treatment arms were comparable, with fatigue, neutropenia, anemia, thrombocytopenia, and diarrhea reported as the most common adverse events of any grade. Finally, he concluded that ibrutinib + venetoclax is an effective and safe treatment option for patients with R/R MCL compared with ibrutinib + placebo, and this combination is already a standard-of-care treatment in several countries.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
SYMPATICO study safety run-in: simultaneous ibrutinib plus venetoclax for R/R MCL
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma lacking therapeutic options that prolong progression free and overall survival. In recent years,...
Review | Therapies available or in clinical development for patients with aggressive mantle cell lymphoma in 2020
Chemoimmunotherapy with rituximab followed by autologous stem cell transplant (auto-HSCT) has been the gold standard and the only...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox